Trial Profile
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Head and neck cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- 26 Feb 2024 Planned End Date changed from 1 Dec 2023 to 1 Jul 2024.
- 24 Oct 2023 Planned primary completion date changed from 23 Sep 2023 to 23 Nov 2023.
- 03 Oct 2022 Planned End Date changed from 1 May 2023 to 1 Dec 2023.